| |
GLAXOSMITHKLINE AND ONO TO COLLABORATE ON DEVELOPMENT AND COMMERCIALISATION OF ONO-4128, A NEW CCR5 ANTAGONIST FOR HIV
|
| |
| |
GlaxoSmithKline plc (GSK) and Ono today announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of a cellular chemokine receptor (CCR5) antagonist discovered by Ono, designated as ONO-4128, currently in preclinical development for treatment of HIV infection, as well as associated back-up and follow-on compounds.
Under the terms of the agreement, GSK will have exclusive worldwide development, manufacturing and commercialisation rights for ONO-4128 and certain associated compounds. Ono will receive an up-front payment and clinical and regulatory milestone payments related to the progress of ONO-4128 and associated compounds for treatment of HIV or other diseases, as well as royalties based on total worldwide annual net sales.
In fields other than HIV, Ono retains the exclusive rights to develop and commercialise its CCR5 antagonists in Japan, South Korea and Taiwan.
"GlaxoSmithKline has had considerable experience in the discovery and development of HIV products and we are delighted to collaborate with Ono for the development of this interesting new class of compounds", said Ken Batchelor, Senior Vice President, Metabolic & Viral Diseases Centre of
Excellence for Drug Discovery at GlaxoSmithKline.
"In order to achieve worldwide development and early launch of ONO-4128, we are delighted to collaborate with GSK, a leading pharmaceutical company with a strong track record in developing and marketing products for the treatment of HIV", said Dr. Kigen Kondo, Executive Director, Research Headquarters at Ono.
The CCR5 receptor is believed to be the predominant co-receptor used by HIV in the early and middle stages of infection. Blocking the CCR5 receptor with an antagonist may offer a novel mechanism for inhibiting HIV infection.
GSK plans to initiate Phase I clinical studies in the USA in the first half of 2003.
|
|
| |
| |
|
|
|
